A randomized phase II study of paclitaxel alone versus paclitaxel plus sorafenib in second- and third-line treatment of patients with HER2-negative metastatic breast cancer (PASO). 19. Oktober 2017 Decker, T., Overkamp, F., Rösel, S., Nusch, A., Göhler, T., Indorf, M., Sahlmann, J., Trarbach, T., 2017. BMC Cancer 17(1), 499. doi:10.1186/s12885-017-3492-1 Abstract Routine treatment and outcome of breast cancer in younger versus elderly patients: results from the SENORA project of the prospective German TMK cohort study. Fietz, T., Zahn, M.-O., Köhler, A., Engel, E., Frank, M., Kruggel, L., Jänicke, M., Marschner, N., Cancer), 2017. Breast Cancer Res Treat 1–12. doi:10.1007/s10549-017-4534-8… Weiterlesen Bevacizumab (Bev)-based combination therapy across treatment lines in patients (pts) with metastatic colorectal cancer (mCRC)-interim analysis results from a German non-interventional study (KORALLE). Eggers, E., Uhlig, J., Reichert, D., Wein, A., Schulz, H., Behringer, A., Arnold, D., 2017. Oncol Res Treat, 40(suppl 3)(P577), 162-163. Weiterlesen